(NASDAQ: FDMT) 4d Molecular Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.
4d Molecular Therapeutics's earnings in 2025 is -$209,177,000.On average, 12 Wall Street analysts forecast FDMT's earnings for 2025 to be -$214,296,526, with the lowest FDMT earnings forecast at -$218,370,257, and the highest FDMT earnings forecast at -$197,973,035. On average, 11 Wall Street analysts forecast FDMT's earnings for 2026 to be -$202,743,814, with the lowest FDMT earnings forecast at -$240,767,206, and the highest FDMT earnings forecast at -$155,978,755.
In 2027, FDMT is forecast to generate -$200,915,491 in earnings, with the lowest earnings forecast at -$277,162,249 and the highest earnings forecast at -$82,188,805.